Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:dateCreated |
1984-6-22
|
| pubmed:abstractText |
Deprenyl combined with levodopa and a peripheral decarboxylase inhibitor is of therapeutic value in the treatment of Parkinson's disease. This conclusion is substantiated by the improvement of akinesia, on-off phases, fluctuations of disability and rigidity. Levodopa doses can be reduced. The onset of adverse reactions is later and side-effects are even milder when compared to those with combined levodopa treatment. The most significant effect of deprenyl, however, is its ability to prolong the life expectancy of parkinsonian patients.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0065-1427
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
95
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
103-5
|
| pubmed:dateRevised |
2007-7-23
|
| pubmed:meshHeading |
pubmed-meshheading:6428140-Dopamine,
pubmed-meshheading:6428140-Drug Therapy, Combination,
pubmed-meshheading:6428140-Humans,
pubmed-meshheading:6428140-Levodopa,
pubmed-meshheading:6428140-Monoamine Oxidase Inhibitors,
pubmed-meshheading:6428140-Outcome and Process Assessment (Health Care),
pubmed-meshheading:6428140-Parkinson Disease,
pubmed-meshheading:6428140-Phenethylamines,
pubmed-meshheading:6428140-Selegiline
|
| pubmed:year |
1983
|
| pubmed:articleTitle |
Deprenyl (selegiline) in the treatment of Parkinson's disease.
|
| pubmed:publicationType |
Journal Article
|